Soleno Therapeutics Is Trading 63% Below Its Lowest Price Target While a $2.5 Billion Buyer Circles

NEW YORK, April 6 —

Oppenheimer just slashed its Soleno Therapeutics price target from $110 to $80. That's now the most bearish call on the Street — and the stock still trades 63% below it. At $39.49 a share, Soleno sits at a 62% discount to the $105 consensus and roughly 20% below the implied per-share value of Neurocrine's reported $2.5 billion acquisition approach. The company has $190 million in trailing revenue and 98.6% gross margins. The stock is priced like a clinical trial just failed, not like a monopoly rare disease drug has a buyer knocking.

What the Street Believes

Wall Street's consensus on Soleno looks almost absurd against the tape. Thirteen analysts carry an average target of $105, implying 166% upside from today's price. Even Oppenheimer, which just delivered the most visible downgrade, kept its Outperform rating and said explicitly that Soleno is "seen beating 2026 sales estimates." The logic is simple: Prader-Willi syndrome is a well-defined genetic condition with a roughly identifiable patient pool. Vykat XR is the first targeted therapy for hyperphagia — the relentless, dangerous hunger that defines the disease. Rare disease drugs with no competition tend to find their patients eventually.

But look at what Oppenheimer actually did, not what it said. The firm didn't trim a target. It lopped off 27% of its valuation in a single move — from $110 to $80 — while insisting the story hasn't changed. That's like saying "the restaurant is great, we just think it has 27% fewer tables than we counted last month." A 27% target cut with a maintained buy rating means one thing: the launch trajectory they modeled was wrong. The question is whether $80 corrects enough.

What the Data Actually Shows

Start with the earnings trajectory, because it tells a story the headline numbers don't. Four quarters ago, Soleno missed estimates by 2.2%, posting a loss of $0.95 per share versus the $0.93 loss expected. Normal early-launch noise. Three quarters ago, the company beat by 80.6%, losing only $0.09 versus the $0.46 loss Wall Street modeled. Then two quarters ago: a $0.47 profit versus $0.06 expected — a 713% beat. Soleno went from burning cash to generating $48 million in trailing free cash flow. That is not a failed launch.

Oppenheimer adjusts price target on Soleno Therapeutics to $80 from $110, maintains Outperform rating, saying Soleno is seen beating 2026 sales estimates despite slower Vykat XR US launch ramp.

Read that again. Oppenheimer is saying two things at once: the launch is slower than modeled, and the company will still beat 2026 revenue expectations. Both can be true if the original models assumed an unrealistically steep initial ramp. Rare disease launches almost never follow the hockey-stick curve sell-side models love. Patients need genetic confirmation. Doctors need to learn the drug exists. Insurers need to build prior authorization pathways. Each step adds weeks or months. None are permanent obstacles.

The 98.6% gross margin tells you the economics in one number. For every dollar of Vykat XR revenue, $0.986 falls to gross profit. That is the margin profile of a rare disease monopoly with zero generic competition. At $190 million in trailing revenue, Soleno already generates real cash. At the $300-400 million peak sales most models assume, it throws off cash like a tollbooth.

Why the Neurocrine Deal Reframes the Math

Reports peg Neurocrine's acquisition approach at roughly $2.5 billion. With the stock at $39.49, Soleno's market cap sits around $2 billion. The reported bid represents approximately a 25% premium to today's price. In rare disease M&A, premiums of 40-60% over the pre-rumor price are standard — acquirers are buying a permanent revenue stream with no generic cliff. If Neurocrine is offering $2.5 billion now, when launch sentiment is weakest, they are buying the dip deliberately.

Consider Neurocrine's position. It is a $14 billion company with deep commercial infrastructure in neuroscience. Prader-Willi syndrome fits squarely in its therapeutic wheelhouse. Neurocrine isn't looking at the same first-quarter prescription data that's spooking public market investors. It's looking at the ten-year revenue stream from the only approved drug for a condition that doesn't go away. The launch slope doesn't matter to an acquirer with a decade-long horizon. It matters enormously to a hedge fund with a quarterly mark.

If the deal closes near $2.5 billion, shareholders get roughly $46-50 per share — a 17-27% premium from here. If the deal doesn't happen but the launch continues its current trajectory (Soleno is already FCF positive at $48 million trailing), the $105 consensus implies the stock needs to nearly triple. Even Oppenheimer's $80 target means a double. The only scenario where $39.49 is the right price: both the acquisition collapses and the launch stalls permanently. That's a parlay bet against a monopoly drug in a genetically defined patient population.

The Bear Case

The bear case deserves real weight. Prader-Willi syndrome affects an estimated 10,000-20,000 people in the US, and the diagnosed, treatment-eligible population could be considerably smaller. If insurers demand extensive prior authorizations or step therapy before covering Vykat XR, the addressable market shrinks fast. Some rare disease launches have taken five or more years to reach even half their modeled peak. A few never got there at all.

There's also deal risk. "Market chatter" about a $2.5 billion acquisition is not a signed merger agreement. Neurocrine could walk away, demand a lower price, or face antitrust complications. Soleno investors who bought at $60 or $70 earlier this year are sitting on painful losses, and sentiment in the shareholder base reflects it. If Q2 prescription trends disappoint again without a deal announcement, the stock could drift lower before it recovers.

But the bear case still doesn't justify $39. The company is already free-cash-flow positive. It has 98.6% gross margins and $190 million in revenue. Even if the launch takes twice as long as bulls expect, the terminal value of a monopoly rare disease drug with these economics sits well above $2 billion. The bet at this price is that a drug already generating $190 million in revenue — for a population with no alternative treatment — will somehow stop growing. That's a hard bet to make.

The Bottom Line

Soleno Therapeutics at $39.49 is priced for a world where the drug launch fails and the acquisition falls apart at the same time. That's not an investment thesis. That's a panic trade. The reported $2.5 billion Neurocrine approach puts a floor somewhere in the mid-$40s. The 98.6% gross margin on $190 million in trailing revenue confirms this is a real commercial business, not a clinical-stage hope story. Oppenheimer cut its target by 27% and still sees the stock doubling from here. The risk-reward tilts sharply for anyone willing to hold through the launch noise. Run the free Soleno Therapeutics, Inc. deep-dive →

What changes my mind: two consecutive quarters of flat or declining prescriptions with no deal announcement by late 2026. That would signal the addressable market is genuinely smaller than modeled — not just slower to capture. Until then, this looks like a rare disease launch following the slow, predictable path every rare disease launch follows. Except this time there's a $2.5 billion buyer standing at the end of it.

Basis Report does not hold positions in securities discussed. This is not investment advice.